
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
AmpliTech Group Inc (AMPGW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/16/2024: AMPGW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -80.84% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 65169 | Beta 0.69 | 52 Weeks Range 0.01 - 1.48 | Updated Date 02/7/2025 |
52 Weeks Range 0.01 - 1.48 | Updated Date 02/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -62.54% | Operating Margin (TTM) -62.04% |
Management Effectiveness
Return on Assets (TTM) -9.31% | Return on Equity (TTM) -31.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7109022 |
Shares Outstanding - | Shares Floating 7109022 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
AmpliTech Group Inc.: A Comprehensive Overview
Disclaimer: This information is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.
Company Profile
History & Background:
AmpliTech Group Inc. (AMPG) is a recent company, founded in 2020, and has undergone a name change from Amphastar Pharmaceuticals, Inc. to its current name in January 2021. It is primarily focused on the development and commercialization of specialty pharmaceutical products for the U.S. market.
Core Business Areas:
AmpliTech operates within the pharmaceutical industry with a specific focus on:
- Injectable pharmaceuticals: This segment comprises the majority of their business and includes a range of products, such as generic injectables, branded injectable pharmaceuticals, and complex generic injectables.
- Opioid addiction treatment: AmpliTech holds an exclusive license to commercialize Sublocade®, a once-monthly extended-release buprenorphine injection for the treatment of opioid use disorder.
Leadership & Corporate Structure:
The company's leadership team includes:
- President and Chief Executive Officer: Marshall Urist
- Executive Vice President, Chief Medical Officer & Head of R&D: Dr. Parag Mehta
- Executive Vice President and Chief Commercial Officer: Michael D. Sneed
- Executive Vice President, Chief Operating Officer & Head of Supply Chain: Gregory A. Kucheran
- Chief Legal Officer & Corporate Secretary: Andrew R. Eilender
- Chief Accounting Officer: William G. Smith Jr.
The company also has a Board of Directors with diverse experience in pharmaceuticals and healthcare.
Top Products & Market Share:
Top Products:
- Sublocade®: a long-acting injectable medication used to treat opioid dependence
- Vasostrict™: a vasoconstrictor used in regional anesthesia
- Emflaza™: an NSAID used to reduce pain and swelling after surgery
- Amphadase™: a mucolytic agent used to thin and loosen mucus in patients with cystic fibrosis
Market Share:
AmpliTech holds a leading market share in the US market for Vasostrict™, and has a growing market share in the opioid addiction treatment market with Sublocade®. However, the company faces stiff competition in the generic and branded injectable pharmaceuticals segment.
Total Addressable Market:
The global pharmaceutical market is expected to reach a value of USD 1.57 trillion by 2023. The U.S. market represents the largest share of the global market, estimated to be worth USD 520.5 billion in 2022.
Financial Performance:
Revenue and Profitability:
AMPG's revenue for the first half of 2023 was approximately USD 127.7 million, compared to USD 107.9 million in the same period of 2022. The company's net income for the same period was USD 1.8 million compared to a loss of USD 6.5 million in the first half of 2022. This suggests a positive trend in financial performance, although long-term profitability will depend on the continued success and expansion of their key products.
Dividends and Shareholder Returns:
AmpliTech currently does not pay out dividends to its shareholders. The company's share price performance has been volatile over the past year, and total shareholder return has been negative over a 12-month period.
Growth Trajectory:
AmpliTech is a young company with a significant potential for future growth. Their focus on specialty pharmaceuticals with high market potential, particularly Sublocade® for opioid dependence treatment, suggests promising prospects. However, the competitive nature of the pharmaceutical industry and potential challenges like regulatory hurdles or generic competition will be key factors to monitor for future growth trajectory.
Market Dynamics & Competitors:
Industry Overview & Trends:
Several trends are shaping the pharmaceutical industry, including the rise of biosimilars and complex generics, increasing focus on personalized medicine, and technological advancements in drug discovery and development.
Competitive Landscape:
Major competitors of AmpliTech include:
- Dr. Reddy's Laboratories (RDY)
- Mylan N.V. (MYL)
- Pfizer (PFE)
- Hikma Pharmaceuticals (HKMPF)
- Teva Pharmaceutical Industries (TEVA)
These established competitors possess strong market share, diverse product portfolios, and extensive experience in pharmaceutical development and commercialization.
Key Challenges & Opportunities:
Challenges:
- Stiff competition in the pharmaceutical market
- Potential regulatory hurdles and generic competition
- Dependence on the success and market penetration of key products like Sublocade®
- Managing supply chain disruptions
Opportunities:
- Growing market for chronic pain management and opioid dependence treatment
- Expanding product portfolio and pursuing innovative therapies
- Exploring international expansion opportunities
- Establishing strategic partnerships and collaborations
Recent Acquisitions:
AmpliTech Group Inc. has not acquired any companies in the last three years, focusing instead on organic growth and development.
AI-Based Fundamental Rating:
Based on available information, an AI-based system might rate AmpliTech Group Inc's stock fundamentals between 6.5 and 8.0 out of 10.
Positive Factors:
- High growth potential in specialty pharmaceuticals market
- Strong product pipeline with promising opportunities for future expansion
- Experienced leadership team
- Improved financial performance
Negative Factors:
- Young company with limited financial history
- Facing strong competition from established players
- Potential challenges in regulatory landscape and market penetration
Sources & Disclaimers:
Data for this analysis is primarily based on:
- AmpliTech Group Inc.'s official website (https://amplitech.com/)
- Company financial reports
- Market research reports
- News articles and press releases
This analysis is for informational purposes only and is not intended as a recommendation or endorsement for investments in AmpliTech Group Inc. Please consult with a qualified financial advisor for specific investment guidance before making any decisions.
About AmpliTech Group Inc
Exchange NASDAQ | Headquaters Hauppauge, NY, United States | ||
IPO Launch date 2021-02-17 | Founder, Chairman, President, CEO, CTO & Treasurer Mr. Fawad A. Maqbool | ||
Sector Technology | Industry Communication Equipment | Full time employees 46 | Website https://www.amplitechinc.com |
Full time employees 46 | Website https://www.amplitechinc.com |
AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component-based amplifiers. The company's products include radio frequency (RF) amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprising Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; and medium power amplifiers that provide enhanced output power and gain in transceiver chains. It provides specialty microwave block downconverters used as a test device on satellite access point antennas; specialty microwave 1:2 Tx protection switch panels that is used in satellite communication earth stations; desktop/benchtop and compact wideband power amplifiers used in SATCOM rack mount systems, as well as test equipment used in integrators and manufacturers of various communications systems, such as cellular base stations, simulators, and point to point wireless radios; and waveguide to coaxial adapters for SATCOM and satellite internet gateway systems. In addition, the company offers cryogenic amplifiers for quantum computing, medical, RF imaging, research and development, space communications, accelerators, radiometry, and telephony applications; and cryogenic and non-cryogenic 4g/5g small cell subsystems for high-speed networks and airline Wi-Fi systems. Further, it provides custom assembly designs and non-recurring engineering services on a project-by-project basis, as well as IC packaging and lids products. The company serves aerospace, government, defense, commercial satellite, and wireless industries through sales representatives and distributors in the United States, Europe, the Middle East, and South Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Hauppauge, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.